Liquid Biopsy Market Size, Share & Industry Analysis, By Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), By Technology (Multi-gene-parallel Analysis, Single Gene Analysis), By Application (Diagnosis & Companion Diagnostics, Treatment Selection & Monitoring, Recurrence/MRD Monitoring, Early Cancer Screening), By End User (Reference/Central Laboratories, Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), By Sample Type (Blood-based, Urine-based, Other Biofluids), and Regional Forecast, 2026-2034
Tell Us How to Tailor This Report
Tick the areas you want changed and describe the requirement in your own words. Nothing is committed at this stage — an analyst reviews it and replies on what's possible.
What Can Be Changed
- Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
- Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
- Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
- Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
- Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
- Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.
What you are already entitled to
Every report includes 10% customisation against the markets it already covers. Licences add free analyst hours on top:
- Single User 30 hours
- Multi User 45 hours
- Enterprise User 60 hours
Where customisation ends
Customisation reshapes what this report already covers. A market, country or industry the study does not cover is a new commissioned study — different scope, different timeline, quoted separately.
Commission a custom study instead →